Yee Huang

Yee Huang

Auto-generated profile, based on publicly available information

Yee Huang

Zhejiang Academy of Agricultural Sciences

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2024 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
YHYee Huang
Yee Huang
JSJiaying Sun
Jiaying Sun
XCXuemei Cui
Xuemei Cui
XLXuefeng Li
Xuefeng Li
ZHZizhe Hu
Zizhe Hu
YLyan liu
yan liu
With the coming of the post‐antibiotic era, there is an increasingly urgent need for safe and efficient antibacterial vaccines. Bacterial outer membrane vesicles (OMVs) have received increased attention recently as a potential subunit vaccine. OMVs are non‐replicative and contain the principle immunogenic bacterial antigen, which circumvents the safety concerns of live‐attenuated vaccines. Here, we developed a novel nano‐vaccine by coating OMVs onto PEGylated nano‐Rehmannia glutinosa polysaccharide (pRL) in a structure consisting of concentric circles, resulting in a more stable vaccine with improved immunogenicity. The immunological function of the pRL‐OMV formulation was evaluated in vivo and in vitro, and the underlying mechanism was studied though transcriptomic analysis. The pRL‐OMV formulation significantly increased dendritic cell (DC) proliferation and cytokine secretion. Efficient phagocytosis of the formulation by DCs was accompanied by DC maturation. Further, the formulation demonstrated superior lymph node targeting, contributing to a potent mixed cellular response and bacterial‐specific antibody response against Bordetella bronchiseptica infection. Specifically, transcriptomic analysis revealed that the immune protection function correlated with T‐cell receptor signalling and Th1/Th2/Th17 differentiation, among other markers of enhanced immunological activity. These findings have implications for the future application of OMV‐coated nano‐carriers in antimicrobial immunotherapy.

1 February 2022 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YHYee Huang
Yee Huang
LNLi Nan
Li Nan
CXChenwen Xiao
Chenwen Xiao
JDJie Dong
Jie Dong
KLKe Li
Ke Li
YLYan Liu
Yan Liu
Purpose: Outer membrane vesicles (OMVs) are spherical nano-sized proteolipids secreted by numerous pathogenic Gram-negative bacteria. Due to the immunostimulatory properties and protective efficacy, OMVs have received increasing attention as a candidate for the vaccine to prevent and treat bacterial infections. However, the immune response remains elusive due to the low structural stability and poor size homogeneity of the vesicles. In this study, OMVs were used to coat self-assembled glycyrrhizic acid nanoparticles (GANs) and obtain a stable OMV vaccine. The immunoprotective effects and anti-infection efficacy were evaluated in vivo and in vitro. Methods: The OMVs were prepared by ultrafiltration method and fused with GAN through mechanical extrusion. The characteristics, including morphology, hydrodynamic size, zeta potential, and stability were evaluated. The in vitro immunological function of GAN-OMV on the macrophages and in vivo immune efficacy and anti-infection effect were examined and compared. Results: The results showed that the GAN-OMV were homogenous with a size of 130 nm and a stable core-shell structure. Micropinocytosis-dependent and clathrin-mediated endocytotic pathways effectively internalized the GAN-OMV into the macrophages and promoted cell proliferation, cytokine secretion, and M1 polarization. Furthermore, subcutaneous GAN-OMV vaccination contributed to significantly higher Borderella bronchiseptica (Bb)-specific antibody production and lymphocyte proliferation. The splenic lymphocytes of mice immunized with GAN-OMVs displayed a higher ratio of CD4+/CD8+ T cells and CD19+ B cells and produced significantly higher levels of Th1/Th2/Th17 cytokines. GAN-OMV also effectively prevented Bb reinfection. Conclusion: In this study, GAN-OMV was developed successfully to stimulate Th1/Th2/Th17 immune responses against Bb and provide a promising strategy for novel vaccine development against the microbial pathogen.

31 March 2025 in World Rabbit Science
Verified
Journal Article
Open access
PDF file
YHYee Huang
Yee Huang
XCXuemei Cui
Xuemei Cui
ZHZizhe Hu
Zizhe Hu
QJQuanan Ji
Quanan Ji
YLYan Liu
Yan Liu
GBGuolian Bao
Guolian Bao
Epidemic diseases have seriously damaged the development of the global rabbit industry. Vaccination plays a vital role in improving the health and welfare of livestock and preventing animal-tohuman transmission, thereby constituting a major public health strategy. There is continued demand for effective and safe adjuvants capable of enhancing antigen-specific responses to a target pathogen of rabbits. Pathogens such as Rabbit Haemorrhagic Disease Virus type 2 (RHDV2), Pasteurella multocida and Eimeria sp. coccidia are lethal and highly contagious for rabbits worldwide. Scientists have been working on screening for immunogenic proteins and designing adjuvant systems for safer and more effective vaccines against these highly prevalent pathogens. With the rapid development of genetic engineering technology and biotechnology, recombinant vaccines, genetic engineering vector vaccines, nucleic acid vaccines and other new vaccines have gradually been developed. Novel adjuvants such as new oil adjuvants, herbal medicine adjuvants, cytokine adjuvants, nano-adjuvants and polysaccharide adjuvants have been applied in the new vaccines to enhance their immunogenicity of new vaccines. Researchers are committed to developing new vaccines with broad spectrum and high efficiency. This review will briefly overview the current research on vaccines and adjuvants against viral, bacterial and parasitic pathogens prevalent in rabbits.